Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
Cartesian Therapeutics (NASDAQ: RNAC) announced that safety and tolerability data for Descartes-08, their lead mRNA cell therapy candidate, will be presented at the 66th ASH Annual Meeting in December 2024. The presentation will focus on their autologous mRNA-engineered CAR-T therapy targeting BCMA. The poster presentation, titled 'Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Diseases,' will be delivered by CMO Miloš Miljković. The poster was also selected for inclusion in the ASH Poster Walk on Blood Immunology & Cellular Therapy.
Cartesian Therapeutics (NASDAQ: RNAC) ha annunciato che i dati sulla sicurezza e la tollerabilità per Descartes-08, il loro candidato principale per la terapia cellulare mRNA, saranno presentati al 66° Congresso Annuale ASH nel dicembre 2024. La presentazione si concentrerà sulla loro terapia CAR-T mRNA ingegnerizzata autologa che mira al BCMA. La presentazione del poster, intitolata 'Sicurezza e Tollerabilità della Terapia con CAR T-Cell mRNA Diretta al BCMA in Mieloma Multiplo e Malattie Autoimmuni,' sarà effettuata dal CMO Miloš Miljković. Il poster è stato inoltre selezionato per essere incluso nella Passeggiata dei Poster dell'ASH sulla Immunologia Ematica e Terapia Cellulare.
Cartesian Therapeutics (NASDAQ: RNAC) anunció que los datos de seguridad y tolerabilidad para Descartes-08, su candidato principal de terapia celular con mRNA, se presentarán en la 66ª Reunión Anual de ASH en diciembre de 2024. La presentación se centrará en su terapia CAR-T de mRNA autóloga dirigida al BCMA. La presentación del póster, titulada 'Seguridad y Tolerabilidad de la Terapia CAR T-Cell de mRNA Dirigida al BCMA en Mieloma Múltiple y Enfermedades Autoinmunes,' será entregada por el CMO Miloš Miljković. El póster también fue seleccionado para ser incluido en el Paseo de Pósters de ASH sobre Inmunología de la Sangre y Terapia Celular.
Cartesian Therapeutics (NASDAQ: RNAC)는 그들의 주요 mRNA 세포 치료 후보인 Descartes-08의 안전성과 내약성 데이터를 2024년 12월 66회 ASH 연례 회의에서 발표할 예정이라고 발표했습니다. 발표는 BCMA를 표적으로 하는 자가 mRNA 엔지니어링 CAR-T 치료에 초점을 맞출 것입니다. '다발성 골수종 및 자가 면역 질환에서 BCMA 지향 mRNA CAR T-세포 치료의 안전성 및 내약성'이라는 제목의 포스터 발표는 CMO인 Miloš Miljković에 의해 이루어질 예정입니다. 이 포스터는 또한 혈액 면역학 및 세포 치료에 관한 ASH 포스터 워크에 포함되도록 선정되었습니다.
Cartesian Therapeutics (NASDAQ: RNAC) a annoncé que les données de sécurité et de tolérance pour Descartes-08, leur principal candidat en thérapie cellulaire à base d'ARNm, seront présentées lors de la 66e Réunion Annuelle de l'ASH en décembre 2024. La présentation se concentrera sur leur thérapie CAR-T à ARNm autologue ciblant le BCMA. La présentation de l'affiche, intitulée 'Sécurité et tolérance de la thérapie CAR T-Cell à ARNm dirigée contre le BCMA dans le myélome multiple et les maladies auto-immunes,' sera réalisée par le CMO Miloš Miljković. L'affiche a également été sélectionnée pour être incluse dans la marche des affiches de l'ASH sur l'immunologie sanguine et la thérapie cellulaire.
Cartesian Therapeutics (NASDAQ: RNAC) gab bekannt, dass die Sicherheits- und Verträglichkeitsdaten für Descartes-08, ihren führenden mRNA-zelltherapeutischen Kandidaten, auf dem 66. ASH Jahresmeeting im Dezember 2024 präsentiert werden. Die Präsentation wird sich auf ihre autologe mRNA-ingenierte CAR-T-Therapie konzentrieren, die auf BCMA abzielt. Die Posterpräsentation mit dem Titel 'Sicherheit und Verträglichkeit der mRNA CAR T-Zelltherapie, die auf BCMA bei multiplen Myelomen und Autoimmunerkrankungen abzielt,' wird vom CMO Miloš Miljković vorgestellt. Das Poster wurde außerdem für die Teilnahme am ASH Poster Walk zur Blutimmunologie und Zelltherapie ausgewählt.
- Selection of company's research for ASH Poster Walk indicates scientific recognition
- Progress in development of lead candidate Descartes-08 reaching presentation stage
- None.
FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego. A copy of the abstract is available on the ASH website at www.hematology.org.
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen (BCMA).
Details of the poster presentation are as follows:
- Publication Number: 2080
- Title: Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Diseases
- Presenter: Miloš Miljković, M.D., M.Sc., Chief Medical Officer, Cartesian Therapeutics
- Session Name: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I
- Session Date/Time: Saturday, December 7, 2024, 5:30-7:30 p.m. PT
- Location: San Diego Convention Center, Halls G-H
In addition, the poster was selected for inclusion in the ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights. The Poster Walk, which aims to highlight cutting-edge emerging science featured at the meeting, will take place on Monday, December 9, 2024, at 7:30 a.m. PT in the Blood Journal Studio located in the Poster Hall.
About Descartes-08
Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product targeting B-cell maturation antigen (BCMA) in clinical development for generalized myasthenia gravis (MG) and systemic lupus erythematosus. In contrast to conventional DNA-based CAR T-cell therapies, mRNA CAR-T administration is designed so that it does not require preconditioning chemotherapy, can be administered in the outpatient setting, and does not carry the risk of genomic integration associated with cancerous transformation. Descartes-08 has been granted Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation by the U.S. Food and Drug Administration for the treatment of MG.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Investor Contact
Melissa Forst
Argot Partners
cartesian@argotpartners.com
Media Contact
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
What will Cartesian Therapeutics (RNAC) present at the 2024 ASH Annual Meeting?
When and where will Cartesian Therapeutics (RNAC) present at ASH 2024?
What is Descartes-08 by Cartesian Therapeutics (RNAC)?
